

## Special Issue

# Metastatic Progression of Human Melanoma

### Message from the Guest Editors

Melanoma is the most metastatic human cancer, and can progress even from a very small sub-millimeter-sized primary. Accordingly, to understand the biology behind it may not only reveal the unique molecular determinants of this biology but may also identify the common, pan-cancer characteristics of metastatic progression. This Special Issue of *Cancers* is dedicated to human melanoma progression. Although there were fundamental improvements in the management of the metastatic disease of melanoma patients, the disease itself is still not curable when it becomes metastatic. To further improve the treatment of melanoma, we have to better understand the biology, the genetic background behind, the unique immunology of melanoma, and most importantly, the background of therapy resistance: chemo-, targeted or immunological. We expect submissions for this endeavor from researchers, molecular pathologists, immunologists and oncologists who can contribute to a better understanding of melanoma.

---

### Guest Editors

Prof. Dr. Jozsef Tímar

2nd Department of Pathology, Semmelweis University, Budapest, Hungary

Dr. Andrea Ladányi

National Institute of Oncology, Budapest, Hungary

---

### Deadline for manuscript submissions

closed (1 January 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/81348](https://mdpi.com/si/81348)

*Cancers*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)